Risk stratification in extranodal natural killer/T-cell lymphoma.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Extranodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoid malignancy characterized by significant biological and clinical heterogeneity.
• Prognosis and established therapeutic approaches for ENKL remain variable, necessitating further research into optimal treatment strategies.
• The management of ENKL involves evolving roles for radiotherapy, chemotherapy, and stem cell transplantation, particularly for early and advanced stages.

Purpose of the Study:

• To discuss key biological, pathogenetic, and clinical factors contributing to ENKL heterogeneity.
• To propose a stratified treatment approach for ENKL based on integrated clinical, pathological, and biological risk factors.
• To highlight the critical need for patient enrollment in clinical trials to identify optimal therapies for ENKL.

Main Methods:

• Review of current literature on the biology, pathogenesis, and clinical presentation of ENKL.
• Analysis of treatment outcomes for various therapeutic modalities, including radiotherapy, chemotherapy, and stem cell transplantation.
• Development of a risk-stratified treatment paradigm for ENKL management.

Main Results:

• Radiotherapy is crucial for early-stage ENKL.
• Advanced ENKL presents an aggressive clinical course with frequent chemotherapy resistance and poor prognosis.
• Asparaginase-based regimens show promise for relapsed ENKL and are being investigated in the frontline setting.

Conclusions:

• Understanding ENKL heterogeneity is key to developing effective treatment strategies.
• A stratified approach based on risk factors can guide ENKL therapy.
• Enrollment in clinical trials is essential for advancing ENKL treatment and improving patient outcomes.